PeptideSearch

Epitalon

Very early research

Get notified when the evidence changes.

The research is at the earliest stage – mostly cells in a lab dish. It is far too early to say much.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-03-30

Also called Epithalon / AEDG peptide / Ala-Glu-Asp-Gly

A four-part peptide studied in Russian ageing research. The work has not been repeated elsewhere and there is no approved use.

The basics

What is it?
A four-part lab-made peptide from Russian research on ageing.
What do we know?
Very little. A handful of Russian papers report effects on ageing markers.
What do we still not know?
Almost everything. Nobody outside those groups has repeated the work.

Official status: Not nominated for 503A compounding · Checked 2026-03-30

Can a doctor prescribe this?

Small pharmacy (503A)
Reviewed by FDA — see timeline
Large outsourcing facility (503B)
Never put forward to FDA

Not FDA approved and not on the 503A bulks list.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 16

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 24 July 2026503A

    FDA proposed that Epitalon NOT be included on the 503A Bulks List.

    FDA briefing documentnot yet verified against primary source

  2. 16 April 2026503A

    FDA published a Federal Register notice announcing a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 at the White Oak campus, to consider seven peptides for the 503A Bulks List.

    Federal Registernot yet verified against primary source

We'll email you when a new study, trial or status change lands for Epitalon. Unsubscribe in one click.